

## Review Form 1.7

Journal Name:	<b>International Research Journal of Oncology</b>
Manuscript Number:	<b>Ms_IRJO_104508</b>
Title of the Manuscript:	<b>Advancing Neurofibromatosis Type 1 Therapies through Basic Research Translation</b>
Type of the Article	<b>Review Article</b>

### **General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journalirjo.com/index.php/IRJO/editorial-policy> )

**Review Form 1.7**

**PART 1: Review Comments**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<p><b>Compulsory REVISION</b> comments</p> <p>1. <b>Is the manuscript important for scientific community?</b> (Please write few sentences on this manuscript)</p> <p>2. <b>Is the title of the article suitable?</b> (If not please suggest an alternative title)</p> <p>3. <b>Is the abstract of the article comprehensive?</b></p> <p>4. <b>Are subsections and structure of the manuscript appropriate?</b></p> <p>5. <b>Do you think the manuscript is scientifically correct?</b></p> <p>6. <b>Are the references sufficient and recent? If you have suggestion of additional references, please mention in the review form.</b></p> <p><b>(Apart from above mentioned 6 points, reviewers are free to provide additional suggestions/comments)</b></p>	<p><b>This is a well written and interesting review of Neurofibromatosis 1.</b> Although there is no cure and current treatments are limited, recent breakthroughs in basic research offer hope for new therapeutic approaches.</p> <p><b>Yes</b></p> <p><b>Yes</b></p> <p><b>Yes</b></p> <p><b>Yes</b></p> <p><b>Yes</b></p>	
<p><b>Minor REVISION</b> comments</p> <p>1. <b>Is language/English quality of the article suitable for scholarly communications?</b></p>	<p>Yes</p>	
<p><b>Optional/General</b> comments</p>	<p>This paper reviews previous strategies, ongoing clinical trials, and recent advances in basic research related to Neurofibromatosis type 1 (NF1) and its associated tumor. The potential of novel therapeutics, including kinase inhibitors, signaling molecule modulators, and microenvironment-targeting drugs have been explored. At this point only one medication has been approved for plexiform neurofibroma treatment. This review provides insights into current strategies, ongoing trials, and recent basic research, aiming to improve treatment outcomes and address unmet needs in NF1 management. Surgery and symptom management remain the main treatment for this benign tumor, but the translation of basic research findings continues to provide the potential of new treatment options. The illustrations and figures in this paper are quite good.</p>	

**PART 2:**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<p><b>Are there ethical issues in this manuscript?</b></p>	<p><i>(If yes, Kindly please write down the ethical issues here in details)</i></p>	

**Reviewer Details:**

Name:	<b>Terry Lichtor</b>
Department, University & Country	<b>Rush University Medical Center, USA</b>